Skip to main content

Prostate-Specific Antigen Levels Posttreatment May Not Predict Overall Survival

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

THURSDAY, Aug. 31, 2023 -- Treatments that reduce the risk for biochemical recurrence (BCR) based on rising prostate-specific antigen levels after radiotherapy do not necessarily improve a patient’s long-term overall survival (OS), according to a study published online Oct. 28 in the Journal of Clinical Oncology.

Soumyajit Roy, M.B.B.S., from Rush University in Chicago, and colleagues conducted a meta-analysis of 11 randomized controlled trials that used treatment intensification strategies with definitive radiotherapy known to reduce BCR to evaluate its surrogacy. For the meta-analysis, individual patient data were collected for each trial for an overall sample of 10,741 patients. The Prentice criteria and the two-stage meta-analytic approach were used to evaluate the surrogacy of BCR-free survival (other-cause mortality as an event) and time to BCR (other-cause mortality as a competing risk).

The researchers found that dose escalation, addition of short-term androgen deprivation therapy (ADT), and prolongation of ADT duration significantly improved BCR (hazard ratios [HRs], 0.71, 0.53, and 0.54, respectively). OS was significantly improved by adding short-term ADT (HR, 0.91) and prolonging ADT (HR, 0.86). However, dose escalation did not improve OS (HR, 0.98; 95 percent confidence interval [CI], 0.87 to 1.11). In all three groups, BCR at 48 months was associated with inferior OS (HRs, 2.46, 1.51, and 2.31, respectively). But when adjusting for BCR at 48 months, there was no significant treatment effect on OS (HR, 1.10 [95 percent CI, 0.96 to 1.27]; HR, 0.96 [95 percent CI, 0.87 to 1.06]; and HR, 1.00 [95 percent CI, 0.90 to 1.12], respectively). For BCR-free survival and OS, the patient-level correlation ranged from 0.59 to 0.69 and time to BCR and OS ranged from 0.23 to 0.41. The correlation of treatment effect on BCR-free survival and time to BCR had R2 levels on OS of 0.563 and 0.160, respectively.

“There was a poor to modest correlation between these BCR-based surrogate end points and OS, suggesting that BCR-based end points are not appropriate surrogate end points,” write the authors.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

First Responders With More Debris Exposure Have Higher Risk of Early Dementia

FRIDAY, June 14, 2024 -- More severe exposure to dust or debris among World Trade Center (WTC) responders is significantly associated with a higher risk of dementia at <65...

1990 to 2019 Saw Increase in Life Expectancy in Seniors With T1DM

FRIDAY, June 14, 2024 -- From 1990 to 2019, there was an increase in life expectancy in older people with type 1 diabetes mellitus (T1DM), according to a study published online...

Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy

FRIDAY, June 14, 2024 -- Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.